Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Wed, 11.08.2021
Formycon AG
Press Release // August 11, 2021
Formycon reports on the status of FYB207 development
- Efficient neutralization of SARS-CoV-2 variants-of-concern
- Production for preclinical and clinical product established at fast track
- Expansion of preclinical efficacy testing planned
- Phase I/IIa clinical trial expected to start first half of 2022
[ … ]
Thu, 05.08.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 5, 2021
Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)
Munich - Formyco [ … ]
Mon, 12.07.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // July 12, 2021
Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A [ … ]
Mon, 05.07.2021
Formycon
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf ADD
herab und bestätigt sein Kursziel von EUR 78,00.
Zusammenfassung:
Im vergangenen November gab Formycon bekannt, dass sie die BLA (Biologics
License Application) für ihr Lucentis-Bio [ … ]
Wed, 30.06.2021
Formycon AG
Press Release // June 30, 2021
Formycon Reports Financial Results for the First Quarter of 2021
- Sales and other earnings total EUR 9.4 million
- EBITDA is EUR -1.7 million
- EBIT and net result in line with expectations at around EUR -2.0 million each
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today presented the sales and ea [ … ]
Tue, 29.06.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 29, 2021
Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA)
Munich - Formycon AG (ISI [ … ]
Mon, 28.06.2021
Formycon AG
Press Release June 28, 2021
Teva Pharmaceutical Industries Ltd. becomes strategic partner for the commercialization of FYB201, Formycon's biosimilar candidate to Lucentis(R)1 (ranibizumab) in Europe, Canada, Israel and New Zealand
Munich - Bioeq AG ("Bioeq"), the exclusive owner of the global commercialization rights of FYB201, Formycon's biosimi [ … ]
Mon, 28.06.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 28, 2021
Formycon announces conclusion of exclusive commercialization agreement between Bioeq AG and Teva Pharmaceutical Industries Ltd. for FYB201 in Europe, Canada, Israel and New Zealand
Munich - Bioeq AG ("Bioeq"), t [ … ]
Thu, 20.05.2021
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf BUY
herauf und bestätigt sein Kursziel von EUR 78,00.
Zusammenfassung:
In ihrem Finanzbericht für das Geschäftsjahr 2020 zeigte Formycon einen
Umsatz von €34,2 Mio. (FBe: &eur [ … ]
Mon, 17.05.2021
Formycon AG
Press Release // May 17, 2021
Formycon Publishes Annual Financial Statements for the 2020 Financial Year
- Group turnover and other earnings total Euro 34.6 million
- Solid liquidity base totaling Euro 49.2 million
- Annual result shaped by scheduled investments in FYB206 and FYB207
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) ha [ … ]